Source link : https://www.newshealth.biz/health-news/no-pfs-benefit-with-immune-checkpoint-inhibitor-rechallenge-in-renal-cell-carcinoma/
The addition of nivolumab (Opdivo) to tivozanib (Fotivda) compared with tivozanib alone failed to improve outcomes as second- or third-line treatment for patients with renal cell carcinoma (RCC) who progressed after immune checkpoint inhibitor (ICI) therapy, according to results from the phase III TiNivo-2 trial. At a median follow-up of 12 months, median progression-free survival […]
Author : News Health
Publish date : 2024-09-13 19:57:59
Copyright for syndicated content belongs to the linked Source.
Categories